Organon & Co., headquartered in Jersey City, develops innovative health solutions in women’s health, biosimilars, and established brands, employing 10,000 people and operating six manufacturing facilities worldwide. The company went public on May 14, 2021, and offers products like Nexplanon and Follistim AQ through various distribution channels.
OGN has been in the news recently: Organon & Co. is facing multiple class action lawsuits related to misleading statements and a significant 70% dividend reduction affecting investors between October 31, 2024, and April 30, 2025. Several law firms are encouraging affected investors, particularly those with losses over $75,000, to join these legal actions before the deadline of July 22, 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.